How We're Keeping You Safe | What Patients & Families Need to Know | Covid-19 Vaccines FAQs
< Back to Pediatric Cancer Research Studies Page
This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least on
To learn more about available leukemia clinical trials, contact us at firstname.lastname@example.org or 513-636-2799.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462
© 1999-2021 Cincinnati Children's Hospital Medical Center. All rights reserved.